- Home
- SGD vs PALI Comparison
SGD vs PALI Comparison
Compare SGD & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- PALI
- Stock Information
- Founded
- SGD 2021
- PALI 1996
- Country
- SGD United States
- PALI United States
- Employees
- SGD N/A
- PALI N/A
- Industry
- SGD
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGD
- PALI Health Care
- Exchange
- SGD Nasdaq
- PALI Nasdaq
- Market Cap
- SGD 3.4M
- PALI 3.5M
- IPO Year
- SGD N/A
- PALI N/A
- Fundamental
- Price
- SGD $2.22
- PALI $1.85
- Analyst Decision
- SGD
- PALI Strong Buy
- Analyst Count
- SGD 0
- PALI 2
- Target Price
- SGD N/A
- PALI $23.00
- AVG Volume (30 Days)
- SGD 131.4K
- PALI 3.7M
- Earning Date
- SGD 01-01-0001
- PALI 11-12-2024
- Dividend Yield
- SGD N/A
- PALI N/A
- EPS Growth
- SGD N/A
- PALI N/A
- EPS
- SGD N/A
- PALI N/A
- Revenue
- SGD $173,188.00
- PALI N/A
- Revenue This Year
- SGD N/A
- PALI N/A
- Revenue Next Year
- SGD N/A
- PALI N/A
- P/E Ratio
- SGD N/A
- PALI N/A
- Revenue Growth
- SGD N/A
- PALI N/A
- 52 Week Low
- SGD $1.45
- PALI $1.38
- 52 Week High
- SGD $53.80
- PALI $22.35
- Technical
- Relative Strength Index (RSI)
- SGD 40.85
- PALI 41.13
- Support Level
- SGD $2.05
- PALI $1.59
- Resistance Level
- SGD $2.40
- PALI $2.20
- Average True Range (ATR)
- SGD 0.24
- PALI 0.38
- MACD
- SGD 0.05
- PALI 0.02
- Stochastic Oscillator
- SGD 26.32
- PALI 19.80
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partner with third-party equity investors or other developers.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.